Brokerages Set Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Target Price at $52.78

by · The Cerbat Gem

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the eleven ratings firms that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, five have assigned a buy rating and two have issued a strong buy rating on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $53.3333.

Several research analysts have weighed in on ARWR shares. Bank of America boosted their price target on Arrowhead Pharmaceuticals from $42.00 to $62.00 and gave the stock a “buy” rating in a research report on Monday, December 1st. B. Riley raised shares of Arrowhead Pharmaceuticals to a “strong-buy” rating in a research note on Monday, August 11th. Royal Bank Of Canada upped their price target on shares of Arrowhead Pharmaceuticals from $45.00 to $52.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 19th. Chardan Capital reissued a “buy” rating and issued a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Monday, December 1st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, October 8th.

Check Out Our Latest Research Report on Arrowhead Pharmaceuticals

Insider Buying and Selling

In other Arrowhead Pharmaceuticals news, Director Mauro Ferrari sold 8,750 shares of the company’s stock in a transaction that occurred on Friday, November 28th. The stock was sold at an average price of $56.39, for a total value of $493,412.50. Following the sale, the director owned 68,764 shares in the company, valued at $3,877,601.96. This represents a 11.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider James C. Hamilton sold 20,000 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $35.00, for a total value of $700,000.00. Following the transaction, the insider owned 212,122 shares of the company’s stock, valued at $7,424,270. This represents a 8.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 43,750 shares of company stock worth $1,643,413. Company insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

Several large investors have recently modified their holdings of ARWR. Moody Lynn & Lieberson LLC acquired a new position in shares of Arrowhead Pharmaceuticals during the 2nd quarter worth approximately $213,000. CWM LLC raised its position in shares of Arrowhead Pharmaceuticals by 159.4% in the second quarter. CWM LLC now owns 11,415 shares of the biotechnology company’s stock valued at $180,000 after buying an additional 7,014 shares in the last quarter. Hsbc Holdings PLC bought a new stake in shares of Arrowhead Pharmaceuticals in the first quarter valued at approximately $173,000. Pinnacle Associates Ltd. grew its position in Arrowhead Pharmaceuticals by 49.9% during the second quarter. Pinnacle Associates Ltd. now owns 211,561 shares of the biotechnology company’s stock worth $3,343,000 after buying an additional 70,399 shares in the last quarter. Finally, Nisa Investment Advisors LLC increased its stake in Arrowhead Pharmaceuticals by 75.9% during the 2nd quarter. Nisa Investment Advisors LLC now owns 3,032 shares of the biotechnology company’s stock worth $48,000 after acquiring an additional 1,308 shares during the period. 62.61% of the stock is owned by institutional investors.

Arrowhead Pharmaceuticals Price Performance

NASDAQ:ARWR opened at $61.44 on Tuesday. Arrowhead Pharmaceuticals has a 52-week low of $9.57 and a 52-week high of $67.14. The company has a market cap of $8.34 billion, a P/E ratio of -767.90 and a beta of 1.28. The company has a debt-to-equity ratio of 0.43, a quick ratio of 4.86 and a current ratio of 4.86. The stock’s 50-day simple moving average is $42.01 and its 200 day simple moving average is $27.56.

Arrowhead Pharmaceuticals Company Profile

(Get Free Report)

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.

Further Reading